Nantong Jinghua Pharmaceutical Co Ltd

Jinghua Pharmaceutical announced on October 11 that it recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial application for its Ji Desheng Snake Tablet to add a new indication for shingles, specifically the liver-gallbladder damp-heat syndrome, has been approved. Ji Desheng Snake Tablet is a marketed traditional Chinese medicine product of the company, with current approved indications being clearing heat and detoxifying, reducing swelling and relieving pain, for use in venomous snake and insect bites.

Jinghua Pharmaceutical announced on October 8 that its grandson company, Nantong Company, has received the Chemical API Marketing Authorization Approval Notice for safinamide mesylate from the National Medical Products Administration. The notice number is 2026YS00941, valid for 60 months, expiring on September 21, 2031. Safinamide mesylate is mainly used for the treatment of Parkinson's disease. This approval marks that Nantong Company is qualified to supply this API in the domestic market. In the first half of 2026, Jinghua Pharmaceutical achieved revenue of 755 million yuan and net profit attributable to the parent of 136 million yuan.

Jinghua Pharmaceutical released its 2026 interim report, with total operating revenue of 755 million yuan, up 3.19% year-on-year, and net profit attributable to the parent of 136 million yuan, up 4.20% year-on-year. Net cash inflow from operating activities was 111 million yuan, the asset-liability ratio was 10.68%, gross margin was 54.26%, ROE was 4.81%, and diluted earnings per share was 0.17 yuan. The number of shareholders was 76,500, and the top ten shareholders held 40.02% of the total share capital.